To test whether FGF1 affects the sensitivity of melanoma cells to BRAF inhibition, we treated the melanoma cell lines M14, UACC-62, and A375 for 5 days with 2 μM vemurafenib in absence or presence of AZD4547, FGF1 or a combination of both (Fig. 4a). The gene discussed is BRAF; the disease is melanoma.